1 – 10 of 30
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Adherence to a restrictive red blood cell transfusion strategy in critically ill patients : An observational study
(
- Contribution to journal › Article
- 2023
-
Mark
An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia : a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study
(
- Contribution to journal › Article
-
Mark
Fetal and neonatal alloimmune thrombocytopenia in 2022 : a response
(
- Contribution to journal › Letter
- 2022
-
Mark
Antenatal intravenous immunoglobulins in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia : comparison of neonatal outcome in treated and nontreated pregnancies
(
- Contribution to journal › Article
-
Mark
Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases
(
- Contribution to journal › Article
- 2021
-
Mark
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
(
- Contribution to journal › Article
-
Mark
Convalescence plasma treatment of COVID-19 : results from a prematurely terminated randomized controlled open-label study in Southern Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
A combined effect of anti-HPA-1a and anti-HLA Class I in pregnancy?
(
- Contribution to journal › Article
-
Mark
The prevalence of HPA-1a alloimmunization and the potential risk of FNAIT depend on both the DRB3*01:01 allele and associated DR-DQ haplotypes
(
- Contribution to journal › Article
-
Mark
Foetal and neonatal alloimmune thrombocytopenia – The role of the HLA-DRB3*01:01 allele for HPA-1a-immunisation and foetal/neonatal outcome
(
- Contribution to journal › Scientific review